675 West 10th Avenue
Dr. Kevin Hay, Clinician Scientist, Terry Fox Laboratory & Leukemia/Bone Marrow Transplant Program of BC, Assistant Professor, Department of Medicine, UBC is speaking at the Diamond Lecture Theatre at the BCCRC February 14th, 2019.
Multi-antigen targeting CAR-T therapy for acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive, clonally heterogeneous malignancy of hematopoietic precursors for which few therapeutic options exist. Adults with relapsed/refractory AML have a dismal prognosis, highlighting the urgent need for novel therapeutics. Cellular immunotherapy with chimeric antigen receptor (CAR-)T cells has demonstrated impressive results in the treatment of B cell malignancies, with remission rates as high as 85%. Spurred by these results, we are developing CAR-T cells targeting AML. I will discuss the challenges of translating this therapy from B cell malignancies to AML, including target antigens, potential toxicity, and the advantage of using a multi-antigen approach.